GET DAILY SIGNALSAutolus (AUTL) Delivers +95% Revenue Growth in Q3 2026 for AUCATZYL
Key Takeaways
- Autolus reported third quarter 2026 AUCATZYL net product revenue of $41.2 million, a 95% increase from $21.1 million a year earlier.
- Net loss narrowed to $55.1 million, or $0.21 per share, compared with a loss of $79.1 million, or $0.30 per share, in the prior-year period.
- Gross margin climbed to 57%, up from 55% in the second quarter of 2026 and a sharp improvement from a negative margin a year ago.
- Management raised its full-year 2026 outlook, now expecting AUCATZYL net product revenue at or above the upper end of $150 million.
- Cash, cash equivalents, and marketable securities totaled $248.4 million, with a projected runway into the second quarter of 2028.
Why This Report Matters
Autolus Therapeutics is an early commercial-stage biopharmaceutical company focused on next-generation programmed T cell therapies. Its lead product, AUCATZYL (obecabtagene autoleucel, or obe-cel), is a chimeric antigen receptor T-cell (CAR-T) therapy used to treat adults with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL). This quarterly update is worth watching because it shows whether a young, high-cost product launch can turn early revenue growth into better margins. In my view, investors are tracking gross margin trends, cash burn, and the pace of treatment-center expansion to gauge whether AUTL can build a sustainable commercial business while advancing a pipeline that reaches into lupus, multiple sclerosis, and pediatric leukemia.
Breaking Down the Reported Results
Autolus reported third quarter 2026 AUCATZYL net product revenue of $41.2 million, up 95% year over year and slightly ahead of consensus estimates. Net loss narrowed to $55.1 million from $79.1 million a year earlier, translating to a basic and diluted net loss of $0.21 per ordinary share versus $0.30 in the third quarter of 2025. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
The clearest sign of progress came in profitability. Gross margin reached 57%, up from 55% in the second quarter and a dramatic swing from a negative margin a year earlier, driven by higher production volumes, lower manufacturing cost per batch, and smaller inventory write-offs. Research and development expense was $30.9 million, while selling, general, and administrative expense was $35.9 million.
Management also raised guidance, now expecting full-year 2026 AUCATZYL net product revenue at or above the upper end of $150 million, marking a third consecutive upgrade from an original range of $120 million to $135 million. The company ended the quarter with $248.4 million in cash, cash equivalents, and marketable securities, supported by a credit facility executed earlier in the year.
Market Reaction and Investor Sentiment
Reaction to the report reflected a mixed picture. The top line exceeded consensus expectations and margins continued their sharp upward trajectory, reinforcing confidence in the AUCATZYL launch. However, revenue declined sequentially from $45.7 million in the second quarter, and management framed the softness as part of a seasonal pattern rather than a demand problem, noting that holiday dynamics and the timing of patient infusions can shift sales between quarters. A delayed readout for the progressive multiple sclerosis program, now expected at ECTRIMS in October 2027, also tempered enthusiasm. Heading into the report, sentiment was cautious, and investors weighed the improving profitability profile against questions about when sequential sales growth would resume.
Forward Outlook and Key Factors to Monitor
Several themes will shape how investors evaluate AUTL in the coming quarters. First, the trajectory of AUCATZYL revenue remains central. Management expanded U.S. treatment centers to 90 and added 18 in the U.K., and deeper use within existing centers is now the primary growth driver. Whether that breadth converts into renewed sequential growth will be closely watched.
Second, the margin story is strengthening but not complete. Gross margin of 57% still has room to rise toward management's longer-term target, and cost discipline across manufacturing and operations will determine how quickly losses narrow further.
Third, the pipeline carries meaningful catalysts. Upcoming data presentations at ASH (American Society of Hematology) are expected to include additional ALL data and the first data for AUTO8 in light-chain amyloidosis. The CARLYSLE study in severe refractory systemic lupus erythematosus (SLE) is also generating longer-term follow-up. Meanwhile, the delayed progressive multiple sclerosis readout shifts one key milestone into late 2027.
Finally, the balance sheet provides runway into the second quarter of 2028, but continued cash use in operating activities means capital efficiency will remain a focus. Investors will monitor these signals without any assurance of future performance.
Using Tickeron Tools in My Research
One tool I rely on for deeper analysis of names like this is Tickeron’s AI Screener. It lets me quickly filter biotech stocks by technical patterns, fundamentals, and AI signals, helping surface comparable setups without hours of manual work. I find it especially useful when tracking margin trends and sector momentum alongside earnings updates.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
AUTL in upward trend: price may ascend as a result of having broken its lower Bollinger Band on November 05, 2026
AUTL may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 36 of 39 cases where AUTL's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where AUTL's RSI Oscillator exited the oversold zone, 24 of 30 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 80%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +4.76% 3-day Advance, the price is estimated to grow further. Considering data from situations where AUTL advanced for three days, in 224 of 261 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for AUTL turned negative on November 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 37 similar instances when the indicator turned negative. In 31 of the 37 cases the stock turned lower in the days that followed. This puts the odds of success at 84%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AUTL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
The Aroon Indicator for AUTL entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 23 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 33 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 71 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.552) is normal, around the industry mean (3.498). P/E Ratio (-1.208) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (4.228) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 80 (best 1 - 100 worst), indicating slightly worse than average price growth. AUTL’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AUTL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of cancer treatments
Industry Biotechnology
Advertisement